Navigation Links
Celladon Corporation Announces Pre-clinical Study Demonstrating Inhalable MYDICAR Reverses Pulmonary Arterial Hypertension (PAH)
Date:7/30/2013

SAN DIEGO, July 30, 2013 /PRNewswire/ -- Celladon Corporation, a clinical-stage biotechnology company committed to applying its first-mover, leadership position in the field of SERCA enzymes to transform the lives of patients with important, life-threatening diseases, announced today that an international team of researchers led by investigators at the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai demonstrate that the deadly condition known as pulmonary arterial hypertension (PAH), which afflicts up to 150,000 Americans each year, may be reversible by using an inhalable form of Celladon's gene therapy product candidate MYDICAR (AAV1/ SERCA2a).

In their new study, reported in the July 30 issue of the journal Circulation, scientists demonstrated that MYDICAR administered through a nebulizer-like inhalation device can completely reverse PAH in rat models of the disease. In the lab, researchers also showed in pulmonary artery PAH patient tissue samples reduced expression of the SERCA2a, an enzyme critical for proper pumping of calcium in calcium compartments within the cells. MYDICAR could therefore be sought as a promising therapeutic intervention in PAH.

Krisztina Zsebo Ph.D., President and CEO of Celladon Corp and a co-author of the study said "Gene therapy represents an entirely new therapeutic modality for the treatment of PAH. We are very excited about the potential of using MYDICAR for this purpose. There is a tremendous need for new treatment options in PAH and we look forward to conducting additional studies investigating the potential benefit of MYDICAR in this patient population."

"The MYDICAR gene therapy could be delivered very easily to patients through simple inhalation — just like the way nebulizers work to treat asthma," says study co-senior investigator Roger J. Hajjar, MD, Director of the Cardiovascular Research Center and the Arthur &
'/>"/>

SOURCE Celladon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech
2. Celladon Corporation To Present at BioCentury Future Leaders in the Biotech Industry Conference
3. Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
4. Celladon Corporation Selected as Winner of Red Herrings "Top 100 North America Tech Startup"
5. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
6. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
7. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
8. Neogen Corporation Announces 2nd Quarter Results Conference Call
9. Luminex Corporation to Present at JP Morgan Healthcare Conference
10. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
11. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... -- Accelovance, a therapeutically focused contract research organization (CRO), ... Organization" at the upcoming Vaccine Industry Excellence (ViE) Awards ... This is the eighth consecutive year Accelovance has been ... "Best Contract Research Organization" in 2009, 2010, and 2011, ... "We,re excited to be a finalist for the ...
(Date:3/25/2015)... An increase of awareness related to benefits of ... nutrients, regulatory changes and concerns related to consumer safety ... natural astaxanthin over the past few years. Producers of ... to satisfy the rising demand. , The global ... in nutraceuticals, aqua feed, food and beverages and cosmetics) ...
(Date:3/25/2015)... 2015 Data from Evidence of ... Action in Neuromuscular Diseases , South San ... (Nasdaq: CYTK) announced the publication of a manuscript ... tirasemtiv in the journal Neurotherapeutics. This publication ... Effect” or hypothesis-generating clinical trial which evaluated tirasemtiv ...
(Date:3/25/2015)... 2015 Researchers at Ancon Medical ... that will enable broader and less invasive screening ... a simple breath screen. The Minnesota-based medical device ... and Drug Administration (FDA) approval process and is ... Nanoparticle Biomarker Tagging device. , Ancon Medicals nanoparticle ...
Breaking Biology Technology:Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 3
... Elenore Bogoch of BioRadar UK Ltd. announced that retrospective studies ... lethal strains of E. Coli preceded the current E. Coli ... in laboratories in Germany and elsewhere since 1995, and genome ... subsequences of the genome of an infectious agent that have ...
... June 20, 2011 Genetic Technologies Limited (ASX: GTG; ... division, Phenogen Sciences Inc., has launched the new BREVAGen™ ... Phenogen Sciences will target its promotion campaign ...  The company has deployed its sales force to service ...
... , Kuros Biosurgery AG, a ... and bioactive-biomaterial,combination products for trauma, wound and spinal ... by the European Patent Office. This now allowed ... portfolio of applications,and patents designed to protect Kuros’ ...
Cached Biology Technology:Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 2Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 3Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US 2Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US 3Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US 4Kuros Announces Allowance of European Patent for Synthetic Biomaterials 2Kuros Announces Allowance of European Patent for Synthetic Biomaterials 3
(Date:3/16/2015)... 16, 2015 Between 16 ... present groundbreaking innovations in biometric identification at the ... .      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ... is well at the forefront: the company,s all ... in Germany . BiometricGate is ...
(Date:3/12/2015)... Beta Systems today announced ... management (IAM) solution for a fixed price and ... new IAM package, customers benefit from the 30 ... IAM implementations across different industries. The new fixed-price ... any necessary services and consulting. It spans the ...
(Date:3/11/2015)... BOSTON , March 11, 2015   ... of its platform to scientifically measure and harness ... characteristics to real-time biometrics and objective measurements of ... of music at scale in large populations. It ... scientists, technologists and clinicians perform rigorous studies and ...
Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3
... may help prevent potentially dangerous bacteria like Staphylococcus ... animals, scientists heard today (Monday 8 September 2008) ... being held this week at Trinity College, Dublin. ... protect them against antibiotics and the body,s natural ...
... Researchers in Switzerland have developed a new ... in microfluidic systems, these "Pyrex"-like nanoparticles are ... and harsh chemical environments than currently used ... Their introduction could extend the range of ...
... INCF Congress of Neuroinformatics will convene September 7-9 ... The emerging neuroinformatics field combines neuroscience and informatics ... understanding the structure and function of the brain. ... disorders and diseases. With a broad international outreach, ...
Cached Biology News:Milk may help bacteria survive against low levels of antibiotics 2INCF organizes the first congress dedicated to the emerging field of neuroinformatics 2